Does Deferasirox Interact with Paclitaxel?
Deferasirox and Paclitaxel have a moderate drug interaction according to U.S. FDA drug labeling data. Deferasirox inhibits CYP2C8 resulting in increased paclitaxel concentration. Monitor for exposure related toxicity. The mechanism involves cyp2c8 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Deferasirox Class
- Iron Chelator
- Paclitaxel Class
- Microtubule Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Deferasirox and Paclitaxel occurs because cyp2c8 inhibition. Clinically, this means deferasirox inhibits cyp2c8 resulting in increased paclitaxel concentration. monitor for exposure related toxicity. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Deferasirox and your doctor is considering prescribing Paclitaxel (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider